Tipifarnib plus tamoxifen in tamoxifen-resistant metastatic breast cancer: A negative phase II and screening of potential therapeutic markers by proteomic analysis

Clinical Cancer Research

Volumn 16, Issue 4, 2010, Pages 1264-1271

  Dalenc, Florence ^a,b   Doisneau Sixou, Sophie F ^a,b,c   Allal, Ben C ^a,d   Marsili, Sabrina ^a   Lauwers Cances, Valérie ^b   Chaoui, Karima ^c,e   Schiltz, Odile ^c,e   Monsarrat, Bernard ^c,e   Filleron, Thomas ^a   Renée, Nicole ^f   Malissein, Emilie ^a,b   Meunier, Elise ^a,b,c   Favre, Gilles ^a,b,c   Roché, Henri ^a,b  

^a INSTITUT CLAUDIUS REGAUD   (France)

^b INSERM   (France)

^c UNIVERSITÉ DE TOULOUSE   (France)

^d EA 3035   (France)

^e INSTITUT DE PHARMACOLOGIE ET DE BIOLOGIE STRUCTURALE   (France)

^f CENTRE ANTOINE LACASSAGNE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FIBRINOGEN; NORTAMOXIFEN; PEPTIDE; PROGESTERONE RECEPTOR; TAMOXIFEN; TIPIFARNIB;

ADULT; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASTHENIA; BONE METASTASIS; BREAST CANCER; BREAST CARCINOMA; CANCER ADJUVANT THERAPY; CANCER GROWTH; CANCER PATIENT; CANCER RELAPSE; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED STUDY; DIARRHEA; DISEASE COURSE; DOSAGE SCHEDULE COMPARISON; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HORMONAL THERAPY; HUMAN; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MAXIMUM TOLERATED DOSE; MEDICAL DECISION MAKING; MUCOSA INFLAMMATION; MULTICENTER STUDY; MYELOID LEUKEMIA; NAUSEA; NEUROTOXICITY; NEUTROPENIA; OPEN STUDY; PHASE 2 CLINICAL TRIAL; POSTMENOPAUSE; PREDICTION; PRIORITY JOURNAL; PROTEOMICS; RASH; SCREENING; STEM CELL TRANSPLANTATION; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; THROMBOCYTOPENIA; TREATMENT DURATION; VEIN THROMBOSIS;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DRUG RESISTANCE, NEOPLASM; FARNESYLTRANSTRANSFERASE; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASMS, HORMONE-DEPENDENT; POSTMENOPAUSE; PROTEIN ARRAY ANALYSIS; QUINOLONES; TAMOXIFEN;

EID: 76749123560     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-09-1192     Document Type: Article

References (29)

1. Nicholson RI, McClelland RA, Robertson JF, Gee JM. Involvement of steroid hormone and growth factor cross-talk in endocrine response in breast cancer. Endocr Relat Cancer 1999;6:373-87.
2. Shou J, Massarweh S, Osborne CK, et al. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J Natl Cancer Inst 2004;96:926-35.
3. Arpino G, Wiechmann L, Osborne CK, Schiff R. Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance. Endocr Rev 2008;29:217-33.
4. Fritz G, Just I, Kaina B. Rho GTPases are over-expressed in human tumors. Int J Cancer 1999;81:682-7.
5. Smith CA, Pollice AA, Gu LP, et al. Correlations among p53, Her-2/neu, and ras overexpression and aneuploidy by multiparameter flow cytometry in human breast cancer: evidence for a common phenotypic evolutionary pattern in infiltrating ductal carcinomas. Clin Cancer Res 2000;6:112-26.
6. Marshall CJ. Protein prenylation-a mediator of protein-protein interactions. Science 1993;259:1865-6.
7. Zhang FL, Casey PJ. Protein prenylation: molecular mechanisms and functional consequences. Annu Rev Biochem 1996;65:241-69.
8. Doisneau-Sixou SF, Cestac P, Chouini S, et al. Contrasting effects of prenyltransferase inhibitors on estrogen-dependent cell cycle progression and estrogen receptor-mediated transcriptional activity in MCF-7 cells. Endocrinology 2003;144:989-98.
9. End DW, Smets G, Todd AV, et al. Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro. Cancer Res 2001;61:131-7.
10. Kelland LR, Smith V, Valenti M, et al. Preclinical antitumor activity and pharmacodynamic studies with the farnesyl protein transferase inhibitor R115777 in human breast cancer. Clin Cancer Res 2001;7:3544-50.
11. Sparano JA, Moulder S, Kazi A, et al. Phase II trial of tipifarnib plus neoadjuvant doxorubicin-cyclophosphamide in patients with clinical stage IIB-IIIC breast cancer. Clin Cancer Res 2009;15:2942-8.
12. Johnston SR, Hickish T, Ellis P, et al. Phase II study of the efficacy and tolerability of two dosing regimens of the farnesyl transferase inhibitor, R115777, in advanced breast cancer. J Clin Oncol 2003; 21:2492-9.
13. Doisneau-Sixou SF, Cestac P, Faye JC, Favre G, Sutherland RL. Additive effects of tamoxifen and the farnesyl transferase inhibitor FTI-277 on inhibition of MCF-7 breast cancer cell-cycle progression. Int J Cancer 2003;106:789-98.
14. Dalenc F, Giamarchi C, Petit M, et al. Farnesyl-transferase inhibitor R115,777 enhances tamoxifen inhibition of MCF-7 cell growth through estrogen receptor dependent and independent pathways. Breast Cancer Res 2005;7:R1159-67.
15. Martin LA, Head JE, Pancholi S, et al. The farnesyltransferase inhibitor R115777 (tipifarnib) in combination with tamoxifen acts synergistically to inhibit MCF-7 breast cancer cell proliferation and cell cycle progression in vitro and in vivo. Mol Cancer Ther 2007;6:2458-67.
16. Lebowitz PF, Eng-Wong J, Widemann BC, et al. A phase I trial and pharmacokinetic study of tipifarnib, a farnesyltransferase inhibitor, and tamoxifen inmetastatic breast cancer. Clin Cancer Res 2005;11:1247-52.
17. Therasse P, Arbuck SG, Eisenhauer EA, et al., European Organization for Research and Treatment of CancerNational Cancer Institute of the United StatesNational Cancer Institute of Canada. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;92:205-16.
18. Cohen SJ, Gallo J, Lewis NL, et al. Phase I and pharmacokinetic study of the farnesyltransferase inhibitor R115777 in combination with irinotecan in patients with advanced cancer. Cancer Chemother Pharmacol 2004;53:513-8.
19. Milano G, Etienne MC, Frenay M, et al. Optimised analysis of tamoxifen and its main metabolites in the plasma and cytosol of mammary tumours. Br J Cancer 1987;55:509-12.
20. Roux-Dalvai F, Gonzalez de Peredo A, Simo C, et al. Extensive analysis of the cytoplasmic proteome of human erythrocytes using the peptide ligand library technology and advanced mass spectrometry. Mol Cell Proteomics 2008;7:2254-69.
21. Goetz MP, Rae JM, Suman VJ, et al. Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol 2005;23:9312-8.
22. Goetz MP, Kamal A, Ames MM. Tamoxifen pharmacogenomics: the role of CYP2D6 as a predictor of drug response. Clin Pharmacol Ther 2008;83:160-6.
23. Li T, Christos PJ, Sparano JA, et al. Phase II trial of the farnesyl transferase inhibitor tipifarnib plus fulvestrant in hormone receptor-positive metastatic breast cancer: New York Cancer Consortium Trial P6205. Ann Oncol 2009;20:642-7.
24. Johnston SR, Semiglazov VF, Manikhas GM, et al. A phase II, randomized, blinded study of the farnesyltransferase inhibitor tipifarnib combined with letrozole in the treatment of advanced breast cancer after antiestrogen therapy. Breast Cancer Res Treat 2008;110: 327-35.
25. Gligorov J, Azria D, Namer M, Khayat D, Spano JP. Novel therapeutic strategies combining antihormonal and biological targeted therapies in breast cancer: focus on clinical trials and perspectives. Crit Rev Oncol Hematol 2007;64:115-28.
26. Bertucci F, Goncalves A. Clinical proteomics and breast cancer: strategies for diagnostic and therapeutic biomarker discovery. Future Oncol 2008;4:271-87.
27. Shi Q, Harris LN, Lu X, et al. Declining plasma fibrinogen α fragment identifies HER2-positive breast cancer patients and reverts to normal levels after surgery. J Proteome Res 2006;5:2947-55.
28. Caputo E, Lombardi ML, Luongo V, et al. Peptide profiling in epithelial tumor plasma by the emerging proteomic techniques. J Chromatogr B Analyt Technol Biomed Life Sci 2005;819:59-66.
29. Villanueva J, Shaffer DR, Philip J, et al. Differential exoprotease activities confer tumor-specific serum peptidome patterns. J Clin Invest 2006;116:271-84.